4.6 Article

Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients

Journal

CANCERS
Volume 13, Issue 23, Pages -

Publisher

MDPI
DOI: 10.3390/cancers13236073

Keywords

CAR-T-cell therapy; diffuse large B-cell lymphoma (DLBCL); secondary DLBCL; prognosis; relapse

Categories

Funding

  1. EMPIRIS foundation in Zurich, Switzerland [003-17]

Ask authors/readers for more resources

This study suggests that patients with transformed/secondary lymphoma have a more favorable course after CAR-T-cell therapy compared to patients with de novo lymphoma.
Simple Summary The clinical features predicting favorable outcomes after CAR-T-cell treatment are a matter of ongoing debate. This study aimed to evaluate the potential importance of lymphoma subtypes regarding prognostic significance, mainly to compare transformed versus de novo DLBCL. We found that patients with transformed/secondary lymphoma have a decisively more favorable course after CAR-T-cell therapy than patients with de novo lymphoma. (1) Background: CAR-T-cell therapy is a novel therapeutic option for patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). The parameters that predict a favorable outcome after CAR-T-cell treatment are a matter of ongoing exploration. (2) Methods: We analyzed 36 consecutive patients with r/r DLBCL receiving tisagenlecleucel or axicabtagene ciloleucel at a single academic institution. We hypothesized that lymphoma subtypes (transformed versus de novo DLBCL) are of prognostic importance. We also assessed age, previous treatment, bridging therapy, remission status at the time of CAR-T treatment and at six months, LDH, the occurrence of CRS or ICANS, and CAR-T-DNA ddPCR kinetics for their prognostic impact. (3) Results: CRS was observed in 24 (67%) patients, and ICANS was observed in 14 (39%) patients. CR was achieved in 20 (56%) patients. Achievement of CR within six months after CAR-T was associated with better PFS (p < 0.0001) and OS (p < 0.0001). Remarkably, transformed (=secondary) lymphoma was associated with a better outcome than de novo disease for PFS (p = 0.0093) and OS (p = 0.0209), and the CR rate was 78% versus 33% (p = 0.0176). Mortality in patients with transformed DLBCL was 23% compared with 56% in de novo patients (p = 0.0209). (4) Conclusion: The presence of transformed DLBCL seems to be associated with a more favorable course after CAR-T treatment than that observed in the de novo DLBCL patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available